BIS

ProShares UltraShort Nasdaq Biotechnology
*Unless otherwise stated, data provided by FactSet.

BIS Fund Description

BIS provides -2x exposure to a market-cap weighted index of biotechnology and pharmaceutical companies listed on the NASDAQ.

BIS Factset Analytics Insight

BIS provides daily geared inverse (-2x) exposure to the NASDAQ Biotechnology Index. It charges 95 bps for holding swaps on the index and the iShares Biotech ETF (IBB), which reaches beyond pure biotechnology into pharmaceuticals, and tilts smaller than our benchmark, in addition to excluding NYSE-listed firms. BIS has increased assets to a reasonable level, which has helped liquidity for investors, though spreads are still sizeable. Unfortunately, BIS is the only fund in the inverse biotech space. Note: BIS is a tactical tool. Due to daily compounding, it's unlikely to achieve its stated exposure and returns for longer than a one-day period, but with its high expense ratio, most investors probably won't want to hang onto it for long anyway.

BIS MSCI ESG Analytics Insight

ProShares UltraShort Nasdaq Biotechnology has an MSCI ESG Fund Rating of A based on a score of 6.70 out of 10. The MSCI ESG Fund Rating measures the resiliency of portfolios to long-term risks and opportunities arising from environmental, social, and governance factors. ESG Fund Ratings range from best (AAA) to worst (CCC). Highly rated funds consist of companies that tend to show strong and/or improving management of financially relevant environmental, social and governance issues. These companies may be more resilient to disruptions arising from ESG events.

The fund’s Peer Rank reflects the ranking of a fund’s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. ProShares UltraShort Nasdaq Biotechnology ranks in the 82nd percentile within its peer group and in the 77th percentile within the global universe of all funds covered by MSCI ESG Fund Ratings.

BIS Charts And Performance

  • 1 Month
  • 3 Months
  • YTD
  • 1 Year
  • 3 Years
  • 5 Years
  • Max
Compare
Reset
Select ETFs to compare their performance:
PERFORMANCE [as of 11/11/19] 1 MONTH 3 MONTHS YTD 1 YEAR 3 YEARS 5 YEARS 10 YEARS
BIS -17.38% -9.73% -28.65% -14.62% -18.21% -19.86% --
BIS (NAV) -17.20% -9.83% -28.39% -14.48% -18.22% -19.86% --
NASDAQ Biotechnology Index 9.67% 4.46% 14.01% 2.53% 5.22% 2.66% --
N/A -- -- -- -- -- -- --
All returns over 1 year are annualized. All returns are total returns unless otherwise stated.

BIS Summary Data

ProShares
04/08/10
Open-Ended Fund
0.95%
$21.55M
0.08%

BIS Portfolio Data

1.91%
12/24/19

BIS Index Data

Market Cap
NASDAQ - Listed
N/A

BIS Fund Structure

Yes
No
No Policy
N/A
N/A
High
-2
Daily

BIS Tax Exposures

20.00% / 39.60%
--
No
Cboe Book Viewer
Top Of Book
Last 10 Trades
Bats BZX Real-time Quote -

BIS Factset Analytics Block Liquidity

As of 11/12/19
5
4
3
2
1

This measurement shows how easy it is to trade a $1 million USD block of BIS. BIS is rated a N/A out of 5.

BIS Tradability

62,731
$1.17M
55,162
$1.02M
0.08%
$0.02
0.00%
0.62% / -0.56%
None
0.00%
50,000
1.10
0.03%
--
639
$16.27
N/A

BIS MSCI ESG Ratings

A
6.70 / 10
76.79
81.72
--
--
--